Staurosporine

目录号:S1421 别名: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine是一种有效的PKC抑制剂,在无细胞试验中作用于PKCα,PKCγ 和PKCη,IC50分别为2 nM,5 nM 和 4 nM,对PKCδ(20 nM)和PKCε(73 nM作用较弱,对PKCζ (1086 nM)的活性很低。同时 对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 2186.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

产品安全说明书

PKC抑制剂选择性比较

生物活性

产品描述 Staurosporine是一种有效的PKC抑制剂,在无细胞试验中作用于PKCα,PKCγ 和PKCη,IC50分别为2 nM,5 nM 和 4 nM,对PKCδ(20 nM)和PKCε(73 nM作用较弱,对PKCζ (1086 nM)的活性很低。同时 对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。
靶点
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
体外研究

Staurosporine 也强抑制HeLa S3细胞,IC50为4 nM。[1]Staurosporine 也抑制多种其他蛋白激酶,包括PKA, PKG, 磷酸激酶, S6 激酶, 肌球蛋白轻链激酶(MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, 和Syk , IC50分别为 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, 和 16 nM。[3] Staurosporine (1 μM) 诱导 PC12细胞90%以上凋亡,这种作用可被过量表达的Bcl-2抑制,或者zVAD-fmk, cycloheximide (10 μM) 及actinomycin D (5 μM)处理也可抑制。相应地, Staurosporine处理,诱导细胞内游离钙水平 [Ca2+]i快速且持久的提升,线粒体活性氧(ROS)的积累,及 随后的线粒体功能障碍。[4]通过caspase-8激活和Bid 分裂,功能性caspase-3的表达可增强Staurosporine诱导MCF7细胞死亡。[5] 1 μM Staurosporine处理,只部分抑制IL-3刺激的Bcl2 磷酸化,而完全阻断PKC调节的 Bcl2磷酸化。[6] Staurosporine 诱导人类包皮成纤维细胞AG-1518凋亡,根据溶酶体组织蛋白酶D调节的 细胞色素 c释放和 caspase 激活。[7] 除了激活传统线粒体凋亡通路, Staurosporine触发一种新型内在凋亡通路, 依赖Apaf-1存在时对caspase-9的激活。[8]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells M3;XSGN6fG:2b4jpZ:Kh[XO|YYm= MkDMOFghcA>? MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NHWtNFYh|ryPLh?= NIjTXYczOTN6OEG5NS=>
human colon cancer cell line (LoVo cells) NIP6enZRem:uaX\ldoF1cW:wIHHzd4F6 NIXjdpNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIHPvcI9vKGOjbnPldkBk\WyuIHzpcoUhMEyxVn:gZ4VtdHNrIIXzbY5oKE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0v M{DCUlEyPTlzNUC1
human LoVo cells NWTORpFlWHKxbHnm[ZJifGmxbjDhd5NigQ>? NE\zcVY1QCC2bzC3NkBp NIjZVWdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzvWo8h[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigQ>? MlSwNlIyQDJ7Mkm=
P19 cells NEPXWGxHfW6ldHnvckBie3OjeR?= NYPHSmxUUW6qaXLpeIlwdiCxZjDQcIF1\WyndD3k[ZJqfmWmIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTBwMECyJO69VS5? MXqxOVc4OTRzOR?=
human BJ cells M2D6WGN6fG:2b4jpZ:Kh[XO|YYm= MmTBO|IhcA>? MmTpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPhcINmcW5iQV2gZZN{[XluIFnDOVA:OC5yMEKg{txONg>? M2q3d|IzQTJzMEix
human HT-29 cells NXnifHdSTnWwY4Tpc44h[XO|YYm= MlXlNkBp NISz[|ZG\m[nY4Sgc44hdWm2b3Poc45lemmjbDDt[Y1jemGwZTDwc5RmdnSrYXygbY4hcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgNkBpenNidYPpcochUkNvMTDzeIFqdmmwZzDifUBndHWxcnXzZ4Vv[2ViYYPzZZk> MlXoNlE1Ojh|N{W=
human A549 cells M3LQXmN6fG:2b4jpZ:Kh[XO|YYm= NHGwWnE4OiCq MoW2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDt[ZRpd2R? MUKxPFQ5PDd5NR?=
human HT-29 cells NXzMTJpNTnWwY4Tpc44h[XO|YYm= MoL5TY5pcWKrdHnvckBw\iCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJJBwfGWwdHnhcEBqdiCqdX3hckBJXC1{OTDj[YxteyC3c3nu[{BLSzFiZInlJJN1[WmwaX7nJIJ6KG[udX;y[ZNk\W6lZTDwcIF1\SC{ZXHk[ZIh[XO|YYmsJGlEPTB;Mj61JI5O M4W0bFIyPTF|Mkmz
human HT-29 cells MWnGeY5kfGmxbjDhd5NigQ>? M1S3dFIhcA>? MXnJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiWLUK5JINmdGy|IHHzd4V{e2WmIILl[JVkfGmxbjDv[kBucXSxY3jvcoRzcWGuIH3lcYJz[W6nIIDveIVvfGmjbDDh[pRmeiB{IHjyd{BjgSC3c3nu[{BLSzFic4ThbY5qdmdiYomg[ox2d3Knc3PlcoNmKGOnbHytZoF{\WRiYYPzZZktKEWFNUC9Nk43KG6PLh?= MX6yNVk4OzFyMR?=
Sf9 cells MVXGeY5kfGmxbjDhd5NigQ>? NHTDNoJKdmirYnn0bY9vKG:oIHj1cYFvKFO7azDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{NCCLQ{WwQVMhdk1w NVvzVZNqOTh6MkO3PFQ>
human HUVEC MXvQdo9tcW[ncnH0bY9vKGG|c3H5 NGnHWpo1QCC2bzC3NkBp M3jrR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGXWSWMh[W[2ZYKgOFghfG9iN{KgbJJ{KGK7IF3UWEBie3OjeR?= NW\4WFZnOjJzOEK5Nlk>
P19 cells Ml[zSpVv[3Srb36gZZN{[Xl? NF3lVIVKdmirYnn0bY9vKG:oIGDyc5RmcW5iS3nuZZNmKEFiaX6gVFE6KGOnbHzzMEBKSzVyPUSgcm0v M1Hk[FE2PzdzNEG5
Sf9 cells NWDleVltTnWwY4Tpc44h[XO|YYm= NUPze2ozUW6qaXLpeIlwdiCxZjDoeY1idiCIeX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjZoTldkAyKG2rbjDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGC= M1HaZ|E4OzF3OEWz
Sf21 cells NIHsXmxHfW6ldHnvckBie3OjeR?= NHL4UGNKdmirYnn0bY9vKG:oIFrBT|Mh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOsJGlEPTB;NjDuUU4> MoqzNVcxQDhyNUm=
human colon carcinoma cell line HCT116 NF:5[4dHfW6ldHnvckBie3OjeR?= NXnWdnRCS2:wY3XueJJifGmxbjDy[ZF2cXKnZDDmc5Ih\3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxibHnu[UBJS1RzMU[sJGlEPTB;NjDuUU4> NFfKWZIyPTV|N{O0OS=>
human ST486 cells MYfQdo9tcW[ncnH0bY9vKGG|c3H5 MWq0PEB1dyB5MjDo NXrye4J{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTWFQ5PiClZXzsd{Bi\nSncjC0PEB1dyB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTdibl2u NWXrbHdFOjJzOEK5Nlk>
human MDA-MB-231 cells MV\DfZRwfG:6aXRCpIF{e2G7 MnW4O|IhcA>? M{[x[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJibXX0bI9lNCCJSUWwQVcvOSCwTT6= NXfydVNKOTh2OES3O|U>
P19 cells NYHtOYFLTnWwY4Tpc44h[XO|YYm= NXHLNmFVUW6qaXLpeIlwdiCxZjDDfYNtcW5vZHXw[Y5l\W62IHvpcoF{\SBzIHnuJHAyQSClZXzsd{whUUN3ME24JI5ONg>? NWnL[4lqOTV5N{G0NVk>
human DLD1 cells Mn3BVJJwdGmoZYLheIlwdiCjc4PhfS=> NUWyZ|VMPDhvN{KgbC=> MlO5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGTFSxJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9PUBvVS5? M4DLfFIzOTh{OUK5
insect cells NHjpfolHfW6ldHnvckBie3OjeR?= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCrbUGg[ZhxemW|c3XkJIlvKGmwc3XjeEBk\WyuczDifUBJXFKILDDJR|UxRTFyIH7NMi=> NX\TNpA4OTlzN{mwO|Y>
V79 MZ cells NET6WFFHfW6ldHnvckBie3OjeR?= M3zucWlvcGmkaYTpc44hd2ZiaIXtZY4h[Wymb4P0[ZJwdmVic4nueIhie2ViZYjwdoV{e2WmIHnuJHY4QSCPWjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGGuZH;zeIVzd26nIIP5cpRp\XOrczygTWM2OD1zMTDuUU4> M2fOdVI1PDJ{NUG5
P19 cells M3jNN2Z2dmO2aX;uJIF{e2G7 MU\Jcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTF2IH7NMi=> NYfH[GJ1OTV5N{G0NVk>
Sf9 cells MXvGeY5kfGmxbjDhd5NigQ>? Ml3QNlAhdWmwcx?= NVLFVXZQUW6qaXLpeIlwdiCxZjDoeY1idiCIeX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjZoTldkAzOCCvaX7zJIJ6KEWOSWPBJIlvKHC{ZYPlcoNmKG:oIEGgeY1wdC:OIFHUVEwhUUN3ME2xOUBvVS5? NXP4OXpNOTd|MUW4OVM>
human PBMC M2jZZ2Z2dmO2aX;uJIF{e2G7 NX\2T|c6OjRiaB?= MWTTeZBxemW|c3nvckBw\iCLTEKgdJJw\HWldHnvckBqdiCqdX3hckBRSk2FIHHmeIVzKDJ2IHjyd{BjgSCHTFnTRUwhUUN3ME2xOkBvVS5? MWWxPFU5PTB2Nh?=
human A549 cells NGCwW|BEgXSxdH;4bYPDqGG|c3H5 M3HVXFQ5KGh? NYLYcoZrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6KCxiSVO1NF0zOCCwTT6= NUHGR29ROjV6MkW5N|Q>
human CEM cells NWXxbZM5S3m2b4TvfIlkyqCjc4PhfS=> NG\uVmU4OiCq MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPhcINmcW5iQV2gZZN{[XluIFnDOVA:OjNibl2u Ml7INlI6OjFyOEG=
human HeLa cells NULGRXV{S3m2b4TvfIlkyqCjc4PhfS=> M3jlUlQ5KGh? MnLrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUK1JI5ONg>? M4XtfFI2QDJ3OUO0
human PC3 cells NWjVNIhsS3m2b4TvfIlkyqCjc4PhfS=> MVi0PEBp MnPYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmgMEBKSzVyPUOxJI5ONg>? NVrkcphCOjV6MkW5N|Q>
human SF268 cells M3vi[GN6fG:2b4jpZ:Kh[XO|YYm= MoXkOFghcA>? MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTSlI3QCClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUS0JI5ONg>? MofHNlE2OTN{OUS=
human MCF7 cells NUHZ[oxNS3m2b4TvfIlkyqCjc4PhfS=> NXv2R2lCPDhiaB?= MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NUCgcm0v M4DFdVIyOzh6MUmx
HEK293 cells MYTDfZRwfG:6aXRCpIF{e2G7 MlnkO|IhcA>? NVPCfXBvS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYLHcI8h[XO|YYmsJGlEPTB;NU[gcm0v NH;h[oEzPDd4M{K2Ni=>
HUE cells MoTvSpVv[3Srb36gZZN{[Xl? NGHxOmM6OCCvaX7z MoruTY5pcWKrdHnvckBw\iCYRVfGVlIhcW5iSGXFJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiVlXHSk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hfHKnYYTl[EBnd3JiOUCgcYlveyCkZX\vdoUhXkWJRjDjbIFtdGWwZ3WgZpkhTUyLU1GsJGlEPTB;N{Cgcm0v NGD2SngzODF5MEG2Ny=>
human A431 cells NUnxN3RXS3m2b4TvfIlkyqCjc4PhfS=> NHnpbG0zPCBiaB?= NX6xPXJHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR|MTDj[YxteyCjZoTldkAzPCCqcoOgeZNqdmdiQX7u[ZhqdiCYZV\JWGMweHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{BjgSCPVGSgZZN{[XluIFnDOVA:PzBibl2u NFP2b40zOjV2MUC1NS=>
human Jurkat cells NEXhepVRem:uaX\ldoF1cW:wIHHzd4F6 NIjvTVNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGpCUzNiZYjwdoV{e2mwZzDJUFIue3SrbYXsZZRm\CCqdX3hckBLfXKtYYSgZ4VtdHNuIFnDOVA:PzFibl2u NFTSO2YyQTR{N{KwNy=>
HEK293 cells MXzGeY5kfGmxbjDhd5NigQ>? NFqySXBKdmirYnn0bY9vKG:oIFnMMVghemWuZXHz[UBjgSCKRVuyPVMh[2WubIOg[ZhxemW|c3nu[{BRU0NvYnX0ZVItKEmFNUC9O|chdk1w MUCxOVc4OTRzOR?=
human KE-97 cells NVn0UoZ4S3m2b4TvfIlkyqCjc4PhfS=> MoW0O|IhcA>? M3;zfWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtGNTl5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTNizszNMi=> MmP3NlQ{Ojh{OEO=
human CHOK1 cells M1HMOmN6fG:2b4jpZ:Kh[XO|YYm= M4[1e|Q5KGh? MnG2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2hQUzFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVAvOTNizszNMi=> NF35VpgzOTVzM{K5OC=>
mouse NIH/3T3 cells Mo[zR5l1d3SxeHnjxsBie3OjeR?= M2PyfFk3KGh? MWHDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDOTWgwO1R|IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zKM7:TT6= M2XuNVI1OzZzNUKx
human A2780 cells M3noXGN6fG:2b4jpZ:Kh[XO|YYm= NFjZToU6PiCq MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNkDPxE1w NGT5[oszPDN4MUWyNS=>
human 8505C cells NUnncWRxS3m2b4TvfIlkyqCjc4PhfS=> MkPQPVYhcA>? Mn\UR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gPFUxPUNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= Ml:yNlQ{PjF3MkG=
human 518A2 cells MYLDfZRwfG:6aXRCpIF{e2G7 NIq2XIo6PiCq NVG2OY1wS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hPTF6QUKgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5Nige,:jDDJR|UxRTBwMjFOwG0v MnjVNlQ{PjF3MkG=
human HuH7 cells MnG5R5l1d3SxeHnjxsBie3OjeR?= M32xSlczKGh? NE\tOY1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJfUh5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjNizszNMi=> NVGzWVV3OjR|MkiyPFM>
FL5.12-Akt1 cells NXPrRYk{WHKxbHnm[ZJifGmxbjDhd5NigQ>? MnqyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDGUFUvOTJvQXv0NUBk\WyuczDifUBOXFRiYYPzZZktKEmFNUC9NE4zQSEQvF2u MVmxOlQxOzZ{Nh?=
human MiaPaCa-2 cells NWrPZpJLWHKxbHnm[ZJifGmxbjDhd5NigQ>? MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2rYWDhR4EuOiClZXzsd{whUUN3ME2wMlM4KM7:TT6= MX6xOlQyOzd6MB?=
human BGC823 cells MUjDfZRwfG:6aXRCpIF{e2G7 NYfPNFU2PzJiaB?= M2TnWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJISzh{MzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN6IN88UU4> M{fwc|I1OzJ6Mkiz
human MCF7 cells M{fncGN6fG:2b4jpZ:Kh[XO|YYm= NXnCR4p7QTZiaB?= M1fiO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlQh|ryPLh?= NH\tNFEzPDN4MUWyNS=>
human A549 cells NWLCR3NbS3m2b4TvfIlkyqCjc4PhfS=> MUm5OkBp NYnKNYNDS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPiEQvF2u MUeyOFM3OTV{MR?=
HEK293 cells M3;ubmN6fG:2b4jpZ:Kh[XO|YYm= Mo\ZR5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|LDDFR|UxRTJizszNMi=> MXSyOVMyPjNzNx?=
human Raji cells  M3P5PGN6fG:2b4jpZ:Kh[XO|YYm= MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDSZYpqKGOnbHzzMEBGSzVyPUKg{txONg>? MXGyOVMyPjNzNx?=
human HepG2 cells Mn3sR5l1d3SxeHnjxsBie3OjeR?= NV\sT3BtS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNuIFXDOVA:OiEQvF2u NVLO[npuOjV|MU[zNVc>
human BJ cells NGHOfXdEgXSxdH;4bYPDqGG|c3H5 NETxW|FEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDUiClZXzsd{whTUN3ME2yJO69VS5? NIPocHgzPTNzNkOxOy=>
human U937 cells NYjDXHY5S3m2b4TvfIlkyqCjc4PhfS=> MlTsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVk{PyClZXzsd{whUUN3ME2yJO69VS5? M1zEVVE4ODh6ME[3

... Click to View More Cell Line Experimental Data

体内研究 在局部贫血前,使用Staurosporine(0.1-10 ng)预处理局部贫血沙鼠和大鼠模型,可防止神经元损伤,这种作用存在剂量依赖性,说明CAl锥体细胞死亡涉及PKC。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
细胞实验:[4]
+ 展开
  • Cell lines: PC12
  • Concentrations: 溶于DMSO,终浓度为1 μM
  • Incubation Time: ~32 小时
  • Method: 使用Staurosporine处理细胞32小时。细胞在4%多聚甲醛中混合,然后使用DNA结合染料Hoechst 33342染色。在荧光照明下观察细胞,测定凋亡细胞百分数。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 短暂局部贫血的雄性Mongolian沙鼠或雄性 Wistar大鼠
  • Formulation: 溶于DMSO,然后在盐水中稀释
  • Dosages: ~10 ng
  • Administration: 定向处理到海马双边CA1子域
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 466.53
化学式

C28H26N4O3

CAS号 62996-74-1
稳定性 powder
别名 CGP 41251

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PKC Signaling Pathway Map

相关PKC产品

Tags: 购买Staurosporine | Staurosporine供应商 | 采购Staurosporine | Staurosporine价格 | Staurosporine生产 | 订购Staurosporine | Staurosporine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID